PTGX
NASDAQ · Biotechnology
Protagonist Therapeutics Inc
$146.15
+8.83 (+6.43%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+75.41%
1Y
+186.79%
YTD
+67.64%
Open$145.01
Previous Close$137.32
Day High$146.84
Day Low$139.95
52W High$143.29
52W Low$50.49
Volume—
Avg Volume529.3K
Market Cap8.78B
P/E Ratio—
EPS$-1.80
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$85.10
Above
SMA 200
$67.75
Above
RSI (14)
58.3
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
20 analysts
Price Target
-79.2% upside
Current
$146.15
$146.15
Target
$30.47
$30.47
$24.78
$30.47 avg
$49.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.52M | 38.75M | 743.95M |
| Net Income | -131,585,982 | -98,631,951 | -91,860,800 |
| Profit Margin | -282.8% | -268.7% | -12.4% |
| EBITDA | -158,581,934 | -125,470,839 | -161,541,358 |
| Free Cash Flow | — | — | -86,698,990 |
| Rev Growth | +20.1% | +20.1% | +6.6% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $244.33 | -0.76% | 122.9 | 446.67B |
| AMGN | Amgen Inc | $403.48 | -1.07% | 26.5 | 206.48B |
| GILD | Gilead Sciences Inc | $129.97 | -1.36% | 17.6 | 161.72B |
| VRTX | Vertex Pharmaceuticals Inc | $484.53 | -0.06% | 27.8 | 120.52B |
| REGN | Regeneron Pharmaceuticals | $767.54 | -0.14% | 17.5 | 77.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $217.83 | -4.76% | 47.7 | 27.52B |